Monkeypox virus quadrivalent mRNA vaccine induces antibody responses and cellular immunity and protects mice against Vaccinia virus

• Published in: bioRxiv 2022-11
• Main Authors: Ye Sang, Zhang, Zhen, Liu, Fan, Lu, Haitao, Yu, Changxiao, Sun, Huisheng, Long, Jinrong, Cao, Yiming, Jierui Mai, Wang, Xin, Fang, Jiaxin, Wang, Youchun, Huang, Weijin, Yang, Jing, Wang, Shengqi
• Format: Article
• Language: English
• Subjects: Cell-mediated immunity; COVID-19; Epidemics; Immunoglobulin G; Immunological memory; Lymphocytes B; Lymphocytes T; Memory cells; Mpox; mRNA; mRNA vaccines; Smallpox; Viruses
• DOI: 10.1101/2022.11.22.517500

There is an urgent need for efficient and safe vaccines against the monkeypox virus (MPXV) in response to the rapidly spreading monkeypox epidemic. In the age of COVID-19, mRNA vaccines have been highly successful and emerged as platforms enabling rapid development and large-scale preparation. Here, we have developed two MPXV quadrivalent mRNA vaccines, named mRNA-A-LNP and mRNA-B-LNP, based on two IMVs (A29L and M1R) and two EEVs (A35R and B6R). By administering mRNA-A-LNP and mRNA-B-LNP intramuscularly twice, mice have induced MPXV-specific IgG antibodies and potent Vaccinia virus (VACV)-specific neutralizing antibodies. Additionally, it elicited durable MPXV-specific killer memory T-cell immunity as well as memory B-cell immunity in mice. Furthermore, the passive transfer of sera from mRNA-A-LNP and mRNA-B-LNP-immunized mice protected nude mice against the VACV challenge. In addition, two doses of mRNA-A-LNP and mRNA-B-LNP were also protective against the VACV challenge in mice. Overall, our results demonstrated that mRNA-A-LNP and mRNA-B-LNP appear to be safe and effective vaccine candidates against monkeypox epidemics, as well as against outbreaks caused by other orthopoxviruses, including the smallpox virus.Competing Interest StatementThe authors have declared no competing interest.